| Literature DB >> 27916749 |
Claudia Cooper1, Rebecca Lodwick2, Kate Walters2, Rosalind Raine3, Jill Manthorpe4, Steve Iliffe5,6, Irene Petersen2.
Abstract
Background: UK Dementia Strategies prioritise fair access to mental and physical healthcare. We investigated whether there are inequalities by deprivation or gender in healthcare received by people with dementia, and compared healthcare received by people with and without dementia.Entities:
Keywords: dementia; deprivation; equalities; healthcare disparities; medication; older people; psychotropic drugs
Mesh:
Substances:
Year: 2017 PMID: 27916749 PMCID: PMC5378291 DOI: 10.1093/ageing/afw208
Source DB: PubMed Journal: Age Ageing ISSN: 0002-0729 Impact factor: 10.668
Characteristics of the included patients at first record of dementia
| Characteristic | Number (%) |
|---|---|
| Patients | 68,061 |
| Male | 25,226 (37%) |
| Female | 42,835 (63%) |
| 50–59 | 1,344 (2%) |
| 60–69 | 5,664 (8%) |
| 70–79 | 20,678 (30%) |
| 80–84 | 17,724 (26%) |
| 85–89 | 14,652 (22%) |
| 90+ | 7,999 (12%) |
| England | 52,087 (77%) |
| Scotland | 9,576 (14%) |
| Wales | 4,260 (6%) |
| Northern Ireland | 2,138 (3%) |
| 2002–05 | 16,320 (24%) |
| 2006–09 | 22,851 (34%) |
| 2010–13 | 28,890 (42%) |
| 1 (least deprived) | 16,242 (24%) |
| 2 | 15,366 (23%) |
| 3 | 15,091 (22%) |
| 4 | 12,976 (19%) |
| 5 (most deprived) | 8,386 (12%) |
| Median (IQR) | 4 (2–6) |
IRRs for prescribing prevalence of antipsychotics, hypnotics and anxiolytics in 54,721 people with dementia, obtained from Poisson regression models with GP practice fitted as a random effect[a],[b]
| Covariate | Antipsychotics | Hypnotics | Anxiolytics | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % | Univariable IRR (95% CI) | Multivariable IRR (95% CI) | % | Univariable IRR (95% CI) | Multivariable IRR (95% CI) | % | Univariable IRR (95% CI) | Multivariable IRR (95% CI) | |
| 1 | 7.0 | 1 | 1 | 5.5 | 1 | 1 | 3.9 | 1 | 1 |
| 2 | 7.1 | 0.98 (0.92–1.03) | 0.97 (0.92–1.03) | 5.8 | 1.04 (0.98–1.11) | 1.03 (0.97–1.10) | 4.6 | 1.07 (0.99–1.15) | 1.06 (0.99–1.14) |
| 3 | 8.0 | 1.07 (1.01–1.13) | 1.07 (1.01–1.13) | 5.5 | 0.96 (0.90–1.03) | 0.96 (0.90–1.03) | 4.6 | 1.08 (1.00–1.16) | 1.07 (1.00–1.16) |
| 4 | 6.8 | 0.95 (0.89–1.02) | 0.95 (0.89–1.01) | 5.2 | 0.96 (0.90–1.04) | 0.96 (0.89–1.03) | 3.8 | 0.92 (0.85–1.01) | 0.92 (0.85–1.00) |
| 5 | 7.2 | 0.93 (0.87–1.00) | 0.93 (0.87–1.00) | 5.5 | 1.00 (0.92–1.08) | 0.99 (0.91–1.07) | 4.5 | 1.03 (0.94–1.13) | 1.02 (0.93–1.12) |
| Male | 6.3 | 1 | 1 | 5.1 | 1 | 1 | 3.9 | 1 | 1 |
| Female | 7.7 | 1.17 (1.13–1.22) | 1.18 (1.13–1.23) | 5.7 | 1.08 (1.04–1.13) | 1.06 (1.02–1.12) | 4.5 | 1.11 (1.05–1.16) | 1.13 (1.07–1.19) |
| 50–69 | 4.7 | 0.61 (0.56–0.66) | 0.61 (0.56–0.67) | 2.9 | 0.52 (0.47–0.58) | 0.52 (0.47–0.58) | 3.0 | 0.64 (0.58–0.72) | 0.64 (0.58–0.72) |
| 70–79 | 7.9 | 1 | 1 | 5.8 | 1 | 1 | 4.7 | 1 | 1 |
| 80–84 | 7.3 | 0.89 (0.85–0.94) | 0.89 (0.84–0.93) | 5.7 | 0.95 (0.90–1.01) | 0.95 (0.90–1.01) | 4.3 | 0.88 (0.83–0.94) | 0.87 (0.82–0.93) |
| 85–89 | 7.2 | 0.87 (0.83–0.92) | 0.83 (0.79–0.88) | 5.8 | 0.96 (0.91–1.02) | 0.94 (0.88–0.99) | 4.2 | 0.86 (0.80–0.92) | 0.82 (0.76–0.87) |
| 90+ | 7.2 | 0.86 (0.81–0.91) | 0.82 (0.77–0.87) | 5.9 | 0.98 (0.92–1.05) | 0.96 (0.90–1.03) | 4.2 | 0.84 (0.77–0.90) | 0.79 (0.73–0.85) |
| 2002–05 | 2.9 | 0.43 (0.39–0.46) | 0.42 (0.39–0.46) | 2.4 | 0.46 (0.42–0.50) | 0.46 (0.42–0.50) | 1.3 | 0.29 (0.25–0.32) | 0.28 (0.25–0.32) |
| 2006–09 | 9.4 | 1.33 (1.28–1.38) | 1.32 (1.27–1.38) | 7.1 | 1.32 (1.26–1.38) | 1.32 (1.26–1.38) | 4.8 | 0.99 (0.94–1.04) | 0.98 (0.93–1.03) |
| 2010–13 | 6.9 | 1 | 1 | 5.3 | 1 | 1 | 4.7 | 1 | 1 |
aRate per 100 person-years.
bEstimates from multivariable models adjusted for all other covariates, as well as for country.
IRRs for each of the four healthcare contact outcomes in 54,721 people with dementia, from Poisson regression models with GP practice fitted as a random effect
| Covariate | Surgery consultations | Blood pressure monitoring | Weight monitoring | Annual dementia review (for follow-up 2006 onwards) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rate[ | Univariable IRR (95% CI) | Multivariable[ | % | Univariable IRR (95% CI) | Multivariable[ | % | Univariable IRR (95% CI) | Multivariable[ | % | Univariable IRR (95% CI) | Multivariable[ | |
| 1 | 6.8 | 1 | 1 | 72 | 1 | 1 | 37 | 1 | 1 | 46 | 1 | 1 |
| 2 | 6.8 | 1.00 (1.00–1.01) | 1.00 (0.99–1.00) | 72 | 1.00 (0.98–1.01) | 0.99 (0.98–1.01) | 37 | 0.99 (0.96–1.01) | 0.99 (0.96–1.01) | 47 | 0.99 (0.97–1.02) | 0.99 (0.97–1.01) |
| 3 | 6.8 | 1.01 (1.00–1.02) | 1.00 (1.00–1.01) | 73 | 1.01 (0.99–1.03) | 1.01)1.00 (0.99–1.02) | 38 | 0.99 (0.97–1.02) | 1.00 (0.97–1.03) | 46 | 0.98 (0.96–1.01) | 0.98 (0.95–1.00) |
| 4 | 6.8 | 1.03 (1.03–1.04) | 1.02 (1.01–1.02) | 74 | 1.02 (1.00–1.04) | 1.01 (0.99–1.03) | 39 | 1.02 (0.99–1.04) | 1.01 (0.99–1.04) | 47 | 0.97 (0.94–0.99) | 0.96 (0.94–0.99) |
| 5 | 6.5 | 1.02 (1.01–1.03) | 1.00 (0.99–1.01) | 75 | 1.03 (1.01–1.05) | 1.02 (1.00–1.04) | 40 | 1.02 (0.99–1.06) | 1.02 (0.99–1.05) | 48 | 0.97 (0.94–1.00) | 0.97 (0.94–1.00) |
| Male | 7.3 | 1 | 1 | 75 | 1 | 1 | 41 | 1 | 1 | 46 | 1 | 1 |
| Female | 6.5 | 0.89 (0.89–0.89) | 0.90 (0.90–0.91) | 72 | 0.97 (0.96–0.98) | 0.96 (0.95–0.97) | 36 | 0.87 (0.86–0.89) | 0.91 (0.90–0.93) | 47 | 1.02 (1.00–1.03) | 1.01 (0.99–1.03) |
| 50–59 | 6.7 | 0.94 (0.93–0.96) | 0.99 (0.97–1.00) | 61 | 0.83 (0.78–0.87) | 0.84 (0.80–0.89) | 41 | 0.96 (0.90–1.03) | 0.97 (0.91–1.04) | 38 | 0.84 (0.78–0.90) | 0.84 (0.78–0.91) |
| 60–69 | 6.6 | 0.94 (0.94–0.95) | 0.99 (0.98–0.99) | 67 | 0.91 (0.89–0.94) | 0.93 (0.90–0.95) | 42 | 0.99 (0.96–1.03) | 1.00 (0.97–1.03) | 39 | 0.93 (0.90–0.96) | 0.94 (0.90–0.97) |
| 70–79 | 7.2 | 1 | 1 | 73 | 1 | 1 | 42 | 1 | 1 | 44 | 1 | 1 |
| 80–84 | 7.1 | 0.97 (0.96–0.97) | 0.96 (0.95–0.96) | 75 | 1.02 (1.00–1.04) | 1.01 (1.00–1.03) | 39 | 0.91 (0.89–0.93) | 0.91 (0.89–0.93) | 48 | 1.03 (1.01–1.05) | 1.02 (1.00–1.04) |
| 85–89 | 6.6 | 0.90 (0.90–0.91) | 0.88 (0.88–0.89) | 74 | 1.01 (1.00–1.03) | 1.00 (0.98–1.01) | 34 | 0.81 (0.79–0.83) | 0.79 (0.77–0.81) | 49 | 1.05 (1.03–1.07) | 1.04 (1.02–1.06) |
| 90+ | 5.9 | 0.81 (0.80–0.81) | 0.79 (0.78–0.79) | 72 | 0.99 (0.97–1.01) | 0.97 (0.95–0.99) | 30 | 0.70 (0.68–0.72) | 0.68 (0.66–0.70) | 50 | 1.06 (1.03–1.08) | 1.04 (1.01–1.06) |
| 2002–05 | 6.7 | 0.96 (0.95–0.97) | 1.03 (1.02–1.03) | 64 | 0.83 (0.81–0.84) | 0.85 (0.84–0.87) | 24 | 0.56 (0.55–0.58) | 0.57 (0.55–0.59) | – | – | – |
| 2006–09 | 6.6 | 0.96 (0.96–0.97) | 1.00 (1.00–1.01) | 72 | 0.93 (0.92–0.94) | 0.95 (0.94–0.96) | 35 | 0.80 (0.79–0.82) | 0.81 (0.80–0.83) | 41 | 0.80 (0.78–0.81) | 0.80 (0.79–0.82) |
| 2010–13 | 6.9 | 1 | 1 | 77 | 1 | 1 | 43 | 1 | 1 | 50 | 1 | 1 |
aRate per person-year.
bEstimates from multivariable models adjusted for all other covariates, as well as for country and prescribing index.